Heather Anne Parsons, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Neoplasms | 24 | 2024 | 21025 | 1.270 |
Why?
|
DNA, Neoplasm | 5 | 2017 | 1745 | 1.000 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2024 | 936 | 0.860 |
Why?
|
Neoplasm, Residual | 4 | 2024 | 1007 | 0.820 |
Why?
|
Estrogen Receptor alpha | 2 | 2020 | 580 | 0.610 |
Why?
|
Receptor, erbB-2 | 7 | 2024 | 2554 | 0.490 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2021 | 938 | 0.480 |
Why?
|
Anticarcinogenic Agents | 1 | 2015 | 249 | 0.440 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11712 | 0.430 |
Why?
|
Camptothecin | 2 | 2024 | 590 | 0.360 |
Why?
|
Tamoxifen | 1 | 2015 | 963 | 0.360 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2024 | 9276 | 0.330 |
Why?
|
Neoplasm Metastasis | 6 | 2021 | 4902 | 0.280 |
Why?
|
Immunoconjugates | 2 | 2024 | 949 | 0.270 |
Why?
|
High-Throughput Nucleotide Sequencing | 6 | 2024 | 3616 | 0.260 |
Why?
|
Neoadjuvant Therapy | 3 | 2024 | 2821 | 0.230 |
Why?
|
Neoplasm Proteins | 1 | 2016 | 3610 | 0.230 |
Why?
|
Topoisomerase I Inhibitors | 1 | 2024 | 74 | 0.230 |
Why?
|
Quinolines | 3 | 2024 | 759 | 0.210 |
Why?
|
Mutation | 13 | 2024 | 29932 | 0.200 |
Why?
|
Maintenance | 1 | 2021 | 25 | 0.190 |
Why?
|
Early Detection of Cancer | 1 | 2016 | 3202 | 0.190 |
Why?
|
Semen | 1 | 2023 | 346 | 0.180 |
Why?
|
Burning Mouth Syndrome | 1 | 2000 | 25 | 0.180 |
Why?
|
Prospective Studies | 7 | 2024 | 54303 | 0.170 |
Why?
|
Female | 31 | 2024 | 391270 | 0.170 |
Why?
|
Antineoplastic Agents | 1 | 2021 | 13630 | 0.160 |
Why?
|
Humans | 44 | 2024 | 760621 | 0.150 |
Why?
|
Neoplasms | 7 | 2023 | 22072 | 0.150 |
Why?
|
Inflammatory Breast Neoplasms | 1 | 2019 | 146 | 0.140 |
Why?
|
Centrosome | 2 | 2015 | 207 | 0.140 |
Why?
|
Polymerase Chain Reaction | 3 | 2016 | 6068 | 0.140 |
Why?
|
Prognosis | 4 | 2024 | 29658 | 0.130 |
Why?
|
Chemotherapy, Adjuvant | 2 | 2022 | 3529 | 0.130 |
Why?
|
Phlebotomy | 1 | 2015 | 137 | 0.120 |
Why?
|
DNA Mutational Analysis | 3 | 2017 | 4107 | 0.120 |
Why?
|
Drug Therapy | 1 | 2016 | 504 | 0.110 |
Why?
|
DNA Copy Number Variations | 2 | 2021 | 2013 | 0.110 |
Why?
|
Adult | 13 | 2024 | 219994 | 0.100 |
Why?
|
Sleep Initiation and Maintenance Disorders | 1 | 2021 | 1079 | 0.100 |
Why?
|
Nurses | 1 | 2021 | 2467 | 0.100 |
Why?
|
Loss of Heterozygosity | 1 | 2014 | 659 | 0.100 |
Why?
|
Aged | 11 | 2024 | 169152 | 0.100 |
Why?
|
Middle Aged | 14 | 2024 | 220352 | 0.100 |
Why?
|
Gene Expression Regulation, Neoplastic | 3 | 2016 | 8515 | 0.100 |
Why?
|
Brain Neoplasms | 2 | 2024 | 8986 | 0.090 |
Why?
|
Disease-Free Survival | 1 | 2021 | 6828 | 0.090 |
Why?
|
Premature Birth | 1 | 2022 | 1771 | 0.090 |
Why?
|
DNA Methylation | 1 | 2024 | 4373 | 0.090 |
Why?
|
Mutation, Missense | 2 | 2015 | 2566 | 0.080 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2017 | 1728 | 0.080 |
Why?
|
BRCA2 Protein | 1 | 2014 | 798 | 0.080 |
Why?
|
DNA | 3 | 2023 | 7233 | 0.080 |
Why?
|
BRCA1 Protein | 1 | 2015 | 1147 | 0.080 |
Why?
|
Medical Oncology | 1 | 2020 | 2313 | 0.080 |
Why?
|
Survival Rate | 2 | 2020 | 12808 | 0.080 |
Why?
|
Combined Modality Therapy | 1 | 2020 | 8552 | 0.070 |
Why?
|
Sequence Analysis, DNA | 3 | 2024 | 4713 | 0.070 |
Why?
|
Prevalence | 1 | 2024 | 15687 | 0.070 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2014 | 1096 | 0.070 |
Why?
|
Bone Neoplasms | 1 | 2018 | 2532 | 0.070 |
Why?
|
Models, Genetic | 1 | 2015 | 3442 | 0.060 |
Why?
|
Intracellular Signaling Peptides and Proteins | 1 | 2015 | 2873 | 0.060 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2015 | 2919 | 0.060 |
Why?
|
Biopsy | 1 | 2016 | 6771 | 0.060 |
Why?
|
DNA Topoisomerases, Type I | 1 | 2024 | 108 | 0.060 |
Why?
|
Sulfites | 1 | 2024 | 83 | 0.060 |
Why?
|
Cell Cycle Proteins | 1 | 2015 | 3446 | 0.060 |
Why?
|
Cell Movement | 1 | 2015 | 5206 | 0.050 |
Why?
|
Antigens, Neoplasm | 2 | 2024 | 1998 | 0.050 |
Why?
|
Telomere-Binding Proteins | 1 | 2004 | 119 | 0.050 |
Why?
|
Phthalazines | 1 | 2024 | 383 | 0.050 |
Why?
|
Retrospective Studies | 5 | 2023 | 80372 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2021 | 11152 | 0.050 |
Why?
|
Aged, 80 and over | 2 | 2024 | 58995 | 0.050 |
Why?
|
Hyperesthesia | 1 | 2000 | 23 | 0.040 |
Why?
|
Quality of Life | 1 | 2022 | 13308 | 0.040 |
Why?
|
Platinum | 1 | 2021 | 223 | 0.040 |
Why?
|
GABA Modulators | 1 | 2000 | 109 | 0.040 |
Why?
|
Tongue Diseases | 1 | 2000 | 68 | 0.040 |
Why?
|
Xerostomia | 1 | 2000 | 94 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2015 | 4319 | 0.040 |
Why?
|
Granulocyte Colony-Stimulating Factor | 1 | 2022 | 629 | 0.040 |
Why?
|
Carboplatin | 1 | 2022 | 788 | 0.040 |
Why?
|
Predictive Value of Tests | 1 | 2016 | 15289 | 0.040 |
Why?
|
Nucleosomes | 1 | 2022 | 484 | 0.040 |
Why?
|
Taxoids | 1 | 2022 | 669 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 16939 | 0.040 |
Why?
|
Heterozygote | 2 | 2015 | 2798 | 0.040 |
Why?
|
Breast | 2 | 2019 | 1963 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2020 | 39261 | 0.040 |
Why?
|
Cell Adhesion Molecules | 1 | 2024 | 1602 | 0.040 |
Why?
|
Epigenomics | 1 | 2023 | 936 | 0.040 |
Why?
|
Nucleic Acid Denaturation | 1 | 2017 | 110 | 0.040 |
Why?
|
Alleles | 2 | 2022 | 6898 | 0.040 |
Why?
|
Chromosomes, Human, Pair 18 | 1 | 2018 | 246 | 0.040 |
Why?
|
Chromosomes, Human, Pair 19 | 1 | 2018 | 347 | 0.030 |
Why?
|
Cyclophosphamide | 1 | 2022 | 2221 | 0.030 |
Why?
|
Pain Threshold | 1 | 2000 | 603 | 0.030 |
Why?
|
Microchemistry | 1 | 2015 | 55 | 0.030 |
Why?
|
Cell Proliferation | 3 | 2015 | 10446 | 0.030 |
Why?
|
Alkaline Phosphatase | 1 | 2018 | 865 | 0.030 |
Why?
|
Colony-Forming Units Assay | 1 | 2015 | 351 | 0.030 |
Why?
|
Heredity | 1 | 2015 | 148 | 0.030 |
Why?
|
Paclitaxel | 1 | 2022 | 1736 | 0.030 |
Why?
|
Genotype | 2 | 2023 | 12960 | 0.030 |
Why?
|
Receptors, Estrogen | 1 | 2022 | 2210 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2015 | 869 | 0.030 |
Why?
|
Hematopoiesis | 1 | 2023 | 2050 | 0.030 |
Why?
|
Blood Chemical Analysis | 1 | 2015 | 437 | 0.030 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2022 | 3775 | 0.030 |
Why?
|
Age Factors | 2 | 2021 | 18416 | 0.030 |
Why?
|
Hemolysis | 1 | 2015 | 423 | 0.030 |
Why?
|
Gene Dosage | 1 | 2017 | 1218 | 0.030 |
Why?
|
Radiation Tolerance | 1 | 2015 | 480 | 0.030 |
Why?
|
Hemoglobins | 1 | 2018 | 1521 | 0.030 |
Why?
|
Signal Transduction | 1 | 2015 | 23376 | 0.030 |
Why?
|
Cancer Care Facilities | 1 | 2015 | 424 | 0.030 |
Why?
|
Immunoblotting | 1 | 2015 | 1649 | 0.030 |
Why?
|
Gene Targeting | 1 | 2015 | 839 | 0.030 |
Why?
|
Plasma | 1 | 2015 | 584 | 0.020 |
Why?
|
Aneuploidy | 1 | 2015 | 551 | 0.020 |
Why?
|
Tubulin | 1 | 2015 | 692 | 0.020 |
Why?
|
Genomic Instability | 1 | 2015 | 704 | 0.020 |
Why?
|
Chromosome Aberrations | 1 | 2018 | 1764 | 0.020 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 1 | 2015 | 895 | 0.020 |
Why?
|
Homozygote | 1 | 2015 | 1788 | 0.020 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2018 | 1529 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2015 | 2506 | 0.020 |
Why?
|
Pilot Projects | 1 | 2022 | 8555 | 0.020 |
Why?
|
Computational Biology | 1 | 2021 | 3505 | 0.020 |
Why?
|
Quinazolines | 1 | 2015 | 1363 | 0.020 |
Why?
|
Recurrence | 1 | 2021 | 8482 | 0.020 |
Why?
|
Prostate-Specific Antigen | 1 | 2018 | 2529 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3905 | 0.020 |
Why?
|
Gene Frequency | 1 | 2015 | 3615 | 0.020 |
Why?
|
Thiazoles | 1 | 2015 | 1511 | 0.020 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2015 | 1489 | 0.020 |
Why?
|
Blotting, Western | 1 | 2015 | 5039 | 0.020 |
Why?
|
Animals | 3 | 2016 | 167963 | 0.020 |
Why?
|
Phenotype | 2 | 2015 | 16546 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5781 | 0.020 |
Why?
|
Genome | 1 | 2015 | 1739 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10344 | 0.020 |
Why?
|
Cell Cycle | 1 | 2015 | 2934 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2846 | 0.020 |
Why?
|
Cell Line | 2 | 2015 | 15620 | 0.020 |
Why?
|
Models, Statistical | 1 | 2021 | 5075 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2015 | 4264 | 0.020 |
Why?
|
Phosphatidylinositol 3-Kinases | 1 | 2015 | 2864 | 0.020 |
Why?
|
Survival Analysis | 1 | 2018 | 10182 | 0.020 |
Why?
|
Male | 5 | 2023 | 359744 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12159 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2015 | 5870 | 0.020 |
Why?
|
Primary Health Care | 1 | 2021 | 4647 | 0.020 |
Why?
|
Homeostasis | 1 | 2015 | 3306 | 0.010 |
Why?
|
Baculoviridae | 1 | 2004 | 115 | 0.010 |
Why?
|
Software | 1 | 2017 | 4419 | 0.010 |
Why?
|
Practice Guidelines as Topic | 1 | 2020 | 7475 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2021 | 7408 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2022 | 26181 | 0.010 |
Why?
|
Glutathione Transferase | 1 | 2004 | 565 | 0.010 |
Why?
|
Risk Factors | 2 | 2021 | 74359 | 0.010 |
Why?
|
Oligonucleotides | 1 | 2004 | 588 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2004 | 1991 | 0.010 |
Why?
|
Mice, Knockout | 1 | 2015 | 14372 | 0.010 |
Why?
|
Protein Folding | 1 | 2004 | 867 | 0.010 |
Why?
|
Protein Structure, Tertiary | 1 | 2004 | 3800 | 0.010 |
Why?
|
Cohort Studies | 1 | 2019 | 41335 | 0.010 |
Why?
|
Kinetics | 1 | 2004 | 6377 | 0.010 |
Why?
|
Binding Sites | 1 | 2004 | 6048 | 0.010 |
Why?
|
Prostatic Neoplasms | 1 | 2017 | 11345 | 0.010 |
Why?
|
Risk Assessment | 1 | 2015 | 24123 | 0.010 |
Why?
|
Genetic Predisposition to Disease | 1 | 2015 | 17790 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40165 | 0.010 |
Why?
|
United States | 1 | 2020 | 72461 | 0.010 |
Why?
|
Protein Binding | 1 | 2004 | 9335 | 0.010 |
Why?
|
Escherichia coli | 1 | 2004 | 4219 | 0.010 |
Why?
|
Mice | 1 | 2015 | 81208 | 0.000 |
Why?
|